Promising safety results from the CORAIL trial suggest a place for lurbinectedin in treating platinum-resistant ovarian cancer.

The novel combination of carboplatin, pegylated liposomal doxorubicin, and bevacizumab has a promising safety and efficacy profile.

Patients receiving psychological support in the OVPSYCH2 randomized study showed reduced fear of progression compared with those without support.

Accurate anatomic subtyping, optimal diagnostic imaging, and molecular classification are among the most pressing needs with NETs.

The future of PRRT lies in its use in combination therapies, including PRRT with chemotherapy, immunotherapy, and as neoadjuvant/adjuvant therapy with surgery.

Targeted alpha-particle therapy is in development for targeted radionuclide therapy of NETs, employing alpha decay to treat diseased tissue at close proximity.

Telotristat ethyl is safe and effective in reducing intractable diarrhea in patients with carcinoid syndrome.

An expert working group developed specific ideas for future research programs in NETs, as well as ways to improve access to NET clinical trials.

Radius Health, Inc. (Nasdaq:RDUS) today provided an update on data from the Phase 1 005 clinical study of elacestrant (RAD1901), an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor positive (ER+) breast cancer. The data were presented at a Spotlight Presentation (Abstract 1410) during the 2017 San Antonio Breast Cancer Symposium (SABCS). Elacestrant recently received Fast Track designation from the U.S. Food and Drug Administration.

The combination of abemaciclib plus pembrolizumab is safe and effective in women with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer.